RE: PHAR The FDA approval they earned today has to do with rapid, point of care tests....
Hmmm, what super-duper ratdog is working on rapid, point of care/exposure tests?
There is usually a common theme to stocks I play...
Is NETE a buy here?
I'll take the 88, 24, 22 & 8 cars anyday...
Here is some of the PHAR news>
The ENOX Test, PharmaNetics' first theranostic test to be launched, is currently the subject of an expanded clinical trial, ELECT (EvaLuating Enoxaparin Clotting Times). The trial is designed to investigate the clinical relevance of "enoxaparin clotting times" in order to assist physicians in customizing appropriate therapy and facilitating treatment of patient populations including UA/NQWMI patients who transition to percutaneous coronary interventions. The Company expects to enroll 600 patients at 17 medical centers under the direction of its principal investigator, Dr. David Moliterno, Associate Professor of Medicine at The Cleveland Clinic Foundation.
Commenting on the news, Dr. Moliterno said, "It is great to finally have a quick reliable method for detecting the extent of anticoagulation provided by enoxaparin. This should help bridge the gap between upstream anticoagulation for unstable angina and procedural anticoagulation during percutaneous coronary interventions." Dr. Jimmy Tcheng co-investigator and Associate Professor of Medicine, Duke University Medical Center, added, "Despite a wealth of positive clinical trials data, the physician community has been reticent to switch from unfractionated heparin to enoxaparin because of the inability to monitor the effects of enoxaparin. I believe that the ENOX Test will produce a paradigm shift in the treatment of coronary artery disease. The ENOX Test, the first device that can rapidly detect the effects of enoxaparin at the point of care, provides that last missing link to better patient outcomes." |
